Skip to main content

Table 2 Patient background and molecular status of Cohort 1

From: A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas

 

All

Group Aa

Group Ba

Group Ca

Group Da

p-valueb

Total

758

155

131

237

235

 

Mean Age at diagnosis(year)

53.7

44.7

41.7

56.7

63.4

<0.0001

Sex M/F

426/332

90/65

75/56

134/103

127/108

0.87

Surgery n (%)

 Biopsy only

121 (16)

16 (10)

19 (15)

49 (21)

37 (16)

0.05

KPS n (%)

 100

160 (21)

66 (43)

51 (40)

26 (11)

17 (7)

<0.0001

 90

268 (35)

63 (41)

58 (45)

83 (35)

64 (27)

 80

126 (17)

13 (8)

7 (5)

43 (18)

63 (27)

 70

94 (12)

6 (4)

8 (6)

38 (16)

42 (18)

  − 60

107 (14)

7 (5)

4 (3)

47 (20)

49 (21)

Adjuvant therapy n (%)

 CRT

559/748 (75)

83/150 (55)

70/131 (53)

201/235 (86)

205/232 (88)

<0.0001

 Chemo only

58/748 (8)

32/150 (21)

5/131 (4)

7/235 (3)

14/232 (6)

 RT only

43/748 (6)

4/150 (3)

16/131 (12)

13/235 (6)

10/232 (4)

 None

88/748 (12)

31/150 (21)

40/131 (31)

14/235 (6)

3/232 (1)

Location n(%)

 Cerebrum (with frontal involvement)

370/756 (49)

119/154 (77)

82/131 (63)

86/237 (36)

83/234 (35)

<0.0001

 Cerebrum (other)

348/756 (47)

34/154 (23)

48/131 (37)

122/237(53)

144/234 (63)

 Thalamus

25/756 (3)

1/154 (0.7)

0/131 (0)

18/237 (8)

6/234 (3)

 Infratentorium

13/756 (2)

0/154 (0)

1/131 (0.8)

11/237 (5)

1/234 (0.4)

Histology n (%)

 DA

63 (8)

12 (8)

26 (20)

19 (8)

6 (3)

<0.0001

 AA

106 (14)

7 (5)

33 (25)

38 (16)

28 (12)

 GBM

337 (44)

9 (6)

7 (5)

136 (57)

185 (79)

 OA

67 (9)

30 (19)

28 (21)

6 (3)

3 (1)

 AOA

103 (14)

32 (21)

29 (22)

29 (12)

13 (6)

 OL

47 (6)

39 (25)

6 (5)

2 (1)

0 (0)

 AO

35 (5)

26 (17)

2 (2)

7 (3)

0 (0)

Molecular background n(%)

 Total 1p/19q loss

148/757 (20)

144/155 (93)

4/131 (3)

0/237 (0)

0/234 (0)

<0.0001

  MGMT methylation

386/755 (51)

143/155 (92)

88/129 (68)

72/236 (31)

83/235 (35)

<0.0001

  H3.3/H3.1 mutation

23/510 (5)

1/31 (3)

0/21 (0)

21/233 (9)

1/235 (0.4)

0.0001

  BRAF V600E

12/506 (2)

0/31 (0)

0/21 (0)

9/233 (4)

3/221 (1)

0.21

CDKN2A

 Homozygous Del

116/505 (23)

4/89 (4)

7/86 (8)

37/163 (23)

68/167 (41)

<0.0001

 Heterozygous Del

72/505 (14)

5/89 (6)

6/86 (7)

22/163 (13)

39/167 (23)

 
  1. AA anaplastic astrocytoma, AO anaplastic oligodendroglioma, AOA anaplastic oligoastrocytoma, Chemo Chemotherapy, CRT chemoradiotherapy, DA diffuse astrocytoma, Del Deletion, F Female, GBM glioblastoma, KPS Karnofsky Performance Status, M Male, N/A not available, OA oligoastrocytoma, OL oligodendroglioma, RT radiation therapy
  2. a Group A IDH mutated-TERT mutated, Group B IDH mutated-TERT wid-type, Group C IDH wild-type-TERT wild-type, Group D IDH mutated-TERT mutated
  3. bOne-way ANOVA was applied for age, and Pearson’s chi-square test was done for others in statistical analysis
Back to article page

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us